Andere Sprachen Heron Therapeutics, Inc.

Aktien

A1XB6K

US4277461020

HRTX

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:48:37 29.04.2024			% 5 Tage	% 1. Jan.
2,485 ^USD	+1,43 %		-4,44 %	+45,59 %

23.04.	HERON THERAPEUTICS, INC. : Capital One Securities bleibt bei seiner Kaufempfehlung	ZM
21.03.	Heron Therapeutics, Inc. kündigt Änderungen in der Geschäftsführung mit Wirkung zum 29. März 2024 an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024	24.04.
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City	11.04.
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference	28.03.
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024	21.03.
Heron Therapeutics : Q4 2023 Earnings Call Presentation	14.03.
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	13.03.
Sector Update: Health Care Stocks Slipping Late Afternoon	13.03.
Heron Therapeutics Shares Soar After Q4 Results Beat	13.03.
Heron Therapeutics : Q4 2023 Earnings Call Presentation	12.03.
Heron Therapeutics: Q4 Earnings Snapshot	12.03.
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M	12.03.
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12.03.
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates	12.03.
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	12.03.
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024	28.02.
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef	24.01.
Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures	24.01.
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures	24.01.
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures	24.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Heron Therapeutics, Inc.

Aktien

A1XB6K

US4277461020

HRTX

Andere Sprachen

Filter